Awaiting development: Guidance and quality standards

Showing 151 to 160 of 332

Guidance and quality standards awaiting development
Title	Type
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance
Inebilizumab for treating immunoglobulin G4-related disease [TSID12107]	Technology appraisal guidance
Infant, children and young people's experience of health care	Quality standard
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Insulin efsitora alfa for treating type 2 diabetes in people on daily insulin injections [ID6499]	Technology appraisal guidance
Interventional Correction of Superior Sinus Venosus Defect and Partial Anomalous Pulmonary Venous Drainage	Interventional procedures guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949]	Technology appraisal guidance